WuXi Biologics Responds to U.S. House Draft Bill

Wuxi Biologics (Cayman) (HK:2269) has released an update.

WuXi Biologics (Cayman) Inc., a global biologics CRDMO platform, has issued a voluntary announcement regarding the passage of a U.S. House Draft Bill labeling the company as a ‘biotechnology company of concern.’ The bill, which includes a grandfather clause, is yet to be reviewed by the U.S. Senate and could be subject to changes. The company asserts that it does not pose a security risk, does not deal with human genomics data, and will continue to comply with international laws while monitoring the legislative process.

For further insights into HK:2269 stock, check out TipRanks’ Stock Analysis page.